Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balixafortide - Spexis

Drug Profile

Balixafortide - Spexis

Alternative Names: POL-6326

Latest Information Update: 01 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polyphor
  • Developer Spexis
  • Class Anti-inflammatories; Anti-ischaemics; Antineoplastics; Cardiovascular therapies; Cyclic peptides; Epitopes; Macrocyclic compounds; Peptidomimetics; Vascular disorder therapies
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Myocardial infarction; Stem cell mobilisation
  • Phase I Adenocarcinoma; Kidney disorders
  • Preclinical COVID 2019 infections
  • No development reported Cancer; Coronary artery restenosis; Inflammation; Solid tumours; Wounds

Most Recent Events

  • 01 Dec 2023 Phase-I clinical trials in Adenocarcinoma (Spexis AG website, December 2023)
  • 20 Mar 2023 MedSIR withdraws a planned phase Ib/II trial in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV), in Spain, prior to enrollment initiation, due to funder decision (NCT04826016)
  • 28 Jan 2023 No recent reports of development identified for preclinical development in Cancer(Combination therapy) in Switzerland (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top